CST, 4596S, TRIF Antibody

Polyclonal Antibody for studying TRIF. Validated for Western Blotting,Immunoprecipitation. Highly specific and rigorously validated in-house, TRIF Antibody (CST #4596) is ready to ship. Product Usage Information Western Blotting: 1:1000 Immunoprecipitation: 1:50 Storage Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. Store at -20°C. Do not aliquot the antibody. Protocol Available protocols: Western Blotting, Immunoprecipitation Specificity / Sensitivity TRIF Antibody detects endogenous levels of total human TRIF protein. Species Reactivity: Human Source / Purification Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Ser219 of human TRIF/TICAM-1. Antibodies were purified by peptide affinity chromatography. Background Members of the Toll-like receptor (TLR) family, named for the closely related Toll receptor in , play a pivotal role in innate immune responses (1-4). TLRs recognize conserved motifs found in various pathogens and mediate defense responses (5-7). Triggering of the TLR pathway leads to the activation of NF-κB and subsequent regulation of immune and inflammatory genes (4). The TLRs and members of the IL-1 receptor family share a conserved stretch of approximately 200 amino acids known as the Toll/Interleukin-1 receptor (TIR) domain (1). Upon activation, TLRs associate with a number of cytoplasmic adapter proteins containing TIR domains, including myeloid differentiation factor 88 (MyD88), MyD88-adapter-like/TIR-associated protein (MAL/TIRAP), TIR domain-containing adapter-inducing IFN-β (TRIF), and Toll-receptor-associated molecule (TRAM) (8-10). This association leads to the recruitment and activation of IRAK1 and IRAK4, which form a complex with TRAF6 to activate TAK1 and IKK (8,11-14). Activation of IKK leads to the degradation of IκB, which normally maintains NF-κB in an inactive state by sequestering it in the cytoplasm. TRIF, also known as TIR domain-containing adapter molecule 1 (TICAM-1), is a TIR domain adapter protein described to activate NF-κB and IRF3 and trigger IFN-β production (15,16). Studies using dominant negative forms of TRIF and siRNA targeting TRIF show that TRIF functions downstream of TLR3 and TLR4 in response to dsRNA and LPS, respectively (15-17). TRIF recruits TRAF6-TAK1-TAB2 to the receptor complex, which leads to NF-κB activation (18). In addition, TRIF can trigger signaling of that lead to the induction of apoptosis (19). Alternate Names IIAE6; MGC35334; MyD88-3; Proline-rich, vinculin and TIR domain-containing protein B; PRVTIRB; Putative NF-kappa-B-activating protein 502H; TCAM1; TICAM-1; TICAM1; TIR domain containing adaptor inducing interferon-beta; TIR domain-containing adapter molecule 1; TIR domain-containing adapter protein inducing IFN-beta; TIR domain-containing adaptor molecule 1; toll like receptor adaptor molecule 1; Toll-interleukin-1 receptor domain-containing adapter protein inducing interferon beta; toll-like receptor adaptor molecule 1; TRIF Specification REACTIVITY: H SENSITIVITY: Endogenous MW (kDa): 98 SOURCE: Rabbit